TrialThe oncologist2022

Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial.

Anna Minchom et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.